国际眼科杂志
國際眼科雜誌
국제안과잡지
INTERNATIONAL JOURNAL OF OPHTHALMOLOGY
2015年
4期
659-661
,共3页
杨雪艳%何锦贤%梁先军%曾胜
楊雪豔%何錦賢%樑先軍%曾勝
양설염%하금현%량선군%증성
PDT治疗%雷珠单抗%年龄相关性黄斑变性%脉络膜新生血管
PDT治療%雷珠單抗%年齡相關性黃斑變性%脈絡膜新生血管
PDT치료%뢰주단항%년령상관성황반변성%맥락막신생혈관
PDT treatment%ranibizumab%age-related macular degeneration%choroidal neovascularization
目的：观察 PDT 联合玻璃体腔注射 ranibizumab (雷珠单抗)治疗老年性黄斑变性脉络膜新生血管( choroidal neovascularization,CNV)的疗效。<br> 方法：将符合纳入标准,经吲哚青绿脉络膜血管造影(indocyanine green angiography, ICGA)、光学相干断层扫描( optical coherence tomography, OCT)检查确诊为黄斑区脉络膜新生血管( CNV)患者27例27眼,经PDT治疗后3~7 d内行 ranibizumab 玻璃体腔注射。观察治疗后1,3,6 mo、末次随访时行最佳矫正视力、FFA、ICGA、OCT 检查及有无并发症发生情况。<br> 结果：最佳矫正视力提高17眼(63%),最佳矫正视力稳定6眼(22%),最佳矫正视力下降4眼(15%)。27例27眼治疗前平均渗漏面积为1005.69±105.47μm,治疗后1,3mo后平均875.54±103.27,423.37±79.68μm,与治疗前比较差异有统计学意义(P<0.01),视网膜黄斑中央厚度27例27眼治疗前平均厚度为485.58±122.59μm,治疗后1,3mo后平均398.84±105.32,297.74±89.18μm,与治疗前比较差异有统计学意义(P<0.01)。<br> 结论：PDT 封闭 CNV 后,联合玻璃体内腔内注射ranibizumab,有效阻断新生血管复发,减少PDT再次治疗次数和并发症,可提高治疗效果。
目的：觀察 PDT 聯閤玻璃體腔註射 ranibizumab (雷珠單抗)治療老年性黃斑變性脈絡膜新生血管( choroidal neovascularization,CNV)的療效。<br> 方法：將符閤納入標準,經吲哚青綠脈絡膜血管造影(indocyanine green angiography, ICGA)、光學相榦斷層掃描( optical coherence tomography, OCT)檢查確診為黃斑區脈絡膜新生血管( CNV)患者27例27眼,經PDT治療後3~7 d內行 ranibizumab 玻璃體腔註射。觀察治療後1,3,6 mo、末次隨訪時行最佳矯正視力、FFA、ICGA、OCT 檢查及有無併髮癥髮生情況。<br> 結果：最佳矯正視力提高17眼(63%),最佳矯正視力穩定6眼(22%),最佳矯正視力下降4眼(15%)。27例27眼治療前平均滲漏麵積為1005.69±105.47μm,治療後1,3mo後平均875.54±103.27,423.37±79.68μm,與治療前比較差異有統計學意義(P<0.01),視網膜黃斑中央厚度27例27眼治療前平均厚度為485.58±122.59μm,治療後1,3mo後平均398.84±105.32,297.74±89.18μm,與治療前比較差異有統計學意義(P<0.01)。<br> 結論：PDT 封閉 CNV 後,聯閤玻璃體內腔內註射ranibizumab,有效阻斷新生血管複髮,減少PDT再次治療次數和併髮癥,可提高治療效果。
목적：관찰 PDT 연합파리체강주사 ranibizumab (뢰주단항)치료노년성황반변성맥락막신생혈관( choroidal neovascularization,CNV)적료효。<br> 방법：장부합납입표준,경신타청록맥락막혈관조영(indocyanine green angiography, ICGA)、광학상간단층소묘( optical coherence tomography, OCT)검사학진위황반구맥락막신생혈관( CNV)환자27례27안,경PDT치료후3~7 d내행 ranibizumab 파리체강주사。관찰치료후1,3,6 mo、말차수방시행최가교정시력、FFA、ICGA、OCT 검사급유무병발증발생정황。<br> 결과：최가교정시력제고17안(63%),최가교정시력은정6안(22%),최가교정시력하강4안(15%)。27례27안치료전평균삼루면적위1005.69±105.47μm,치료후1,3mo후평균875.54±103.27,423.37±79.68μm,여치료전비교차이유통계학의의(P<0.01),시망막황반중앙후도27례27안치료전평균후도위485.58±122.59μm,치료후1,3mo후평균398.84±105.32,297.74±89.18μm,여치료전비교차이유통계학의의(P<0.01)。<br> 결론：PDT 봉폐 CNV 후,연합파리체내강내주사ranibizumab,유효조단신생혈관복발,감소PDT재차치료차수화병발증,가제고치료효과。
AIM: To observe the curative effect of PDT combined with intravitreal injection of ranibizumab treatment for age-related macular degeneration with choroidal neovascularization ( CNV) . <br> METHODS:In accordance with the inclusion criteria, by indocyanine green choroidalangiography ( ICGA ) and optical coherence tomography ( OCT ) examination confirmed the diagnosis of macular CNV in 27 patients (27 eyes), treated with PDT 3 ~ 7d professional intravitreal injection of ranibizumab. At 1, 3, 6mo after treatment, the results of best corrected visual acuity (BCVA), FFA, ICGA, OCT examination and complications were observed. <br> RESULTS: The BCVA improved in 17 eyes ( 63%) , stable in 6 eyes ( 22%) , and decreased in 4 eyes ( 15%) . Before treatment, the average leakage area was 1 005. 69±105. 47μm, it were 875. 54 ± 103. 27μm, and 423. 37 ±79.68μm at 1 and 3mo after treatment, there were significant differences compared with before treatment ( P<0. 01). Average central macular thickness of retina before treatment was 485. 58±122. 59μm, and 398. 84±105. 32μm, 297. 74±89. 18μ m at 1 and 3mo after treatment, there were significant differences compared with before treatment( P<0. 01). <br> CONCLUSION: The method that PDT closed CNV combined with intravitreal injection of ranibizumab can effectively block angiogenesis recurrence, reduce the number of PDT treatment again and complications, improve the therapeutic effect.
